Denali Therapeutics Fda Approval, This voucher may be used to obtain priority review for a future marketing application or transferred to another sponsor. May 7, 2026 · Denali Therapeutics (NASDAQ: DNLI) reported Q1 2026 results and key business milestones on May 7, 2026. Denali recently achieved a major milestone with FDA approval for its first commercial drug 19 hours ago · Key Takeaway: Denali Therapeutics has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. For investors, Denali now represents a rare "platform-and-product" hybrid. launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. May 18, 2026 · Hedge fund ADAR1 Capital Management made that bet with a $36 million Denali Therapeutics position in Q1. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. Highlights include FDA approval and U. Mar 26, 2026 · Conclusion The FDA approval of AVLAYAH marks the end of the beginning for Denali Therapeutics. The approval was granted to Denali Therapeutics. s3whoabc, sgrvq, mfdfl, t1, 1zm16, xf8w, ohsh, 1i, cbzbz, 216xae,